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Abstract: The serine protease inhibitor (serpin), plasminogen activator inhibitor-1 (PAI-1), is an
important biomarker for cardiovascular disease and many cancers. It is therefore a desirable target
for pharmaceutical intervention. However, to date, no PAI-1 inhibitor has successfully reached clin-
ical trial, indicating the necessity to learn more about the mechanics of the serpin. Although its
kinetics of inhibition have been extensively studied, less is known about the latency transition of
PAI-1, in which the solvent-exposed reactive center loop (RCL) inserts into its central b-sheet, ren-
dering the inhibitor inactive. This spontaneous transition is concomitant with a large translocation
of the RCL, but no change in covalent structure. Here, we conjugated the fluorescent probe, NBD,
to single positions along the RCL (P13-P50) to detect changes in solvent exposure that occur during
the latency transition. The results support a mousetrap-like RCL-insertion that occurs with a half-
life of 1–2 h in accordance with previous reports. Importantly, this study exposes unique transitions
during latency that occur with a half-life of ~5 and 25 min at the P50 and P8 RCL positions, respec-
tively. We hypothesize that the process detected at P50 represents s1C detachment, while that at
P8 results from a steric barrier to RCL insertion. Together, these findings provide new insights by
characterizing multiple steps in the latency transition.
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Introduction
Plasminogen activator inhibitor-1 (PAI-1) is the
main serpin that slows fibrin clot breakdown by rap-
idly inhibiting tissue- and urokinase-plasminogen
activators.1 PAI-1 uses its reactive center loop
(RCL), which contains the P1–P10 scissile bond, in
the fast, enthalpically driven, suicide inhibition of
target proteases.2–5 However, PAI-1 can spontane-
ously self-inactivate by transition to latent state by
insertion of the RCL into its central scaffold without
a change in covalent structure (Fig. 1).2 The rate of
the latency conversion in PAI-1 is magnitudes slower
than protease inhibition and is entropically driven.6
PAI-1 is unique within the metastable serpin family
for the ability to undergo this transition under
Abbreviations: serpin, serine protease inhibitor; PAI-1, plas-
minogen activator inhibitor-1; RCL, reactive center loop; tPA,
tissue plasminogen activator; uPA, urokinase plasminogen
activator; NBD, N,N0-dimethyl-N-(iodoacetyl)-N0-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)ethylenediamine
Significance: PAI-1 is a labile serpin, and major risk factor in the
development of cardiovascular disease and metastatic cancer.
PAI-1 regulates itself and inactivates by adopting a latent con-
formation. This report is the first characterization of the time-
frame for early and intermediate steps that occur during the
latency transition of PAI-1, a process that is important to ensure
its proper physiological function.
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physiological conditions (378C, pH 7.4) with a half-
life of 1–2 h.6–8
Because its overexpression is associated with a
myriad of conditions (e.g., cardiovascular disease,
cancer metastasis, metabolic syndrome), PAI-1 is
desired as a druggable target, possibly via accelerat-
ing or decelerating the latency transition without
affecting important interactions (i.e., with its cofac-
tor vitronectin).9–12 However, of the existing PAI-1
inhibitors, none have thus far been approved for
clinical testing.12 Clearly, we must learn more about
the latency transition of PAI-1 for the creation of
better inhibitors to interrupt its pathophysiological
functions. Whereas the mechanism of protease inhi-
bition has been thoroughly characterized,13–17 less is
known about the time sequence and coordination of
steps during the latency transition of PAI-1. Struc-
tural requirements have been suggested from crystal
evidence, which include opening of the “shutter,”
detachment of the first strand of b-sheet C (s1C)
continuous with the RCL, widening of the “gate” to
allow RCL passage, displacement, and return of
helix F (hF), and the loop connecting it to strand 3
of b-sheet A (s3A), insertion of the N-terminal RCL
residues into the “shutter,” and elongation of the C-
terminal RCL residues alongside the protein surface
(Fig. 1).18,19 A prelatent state has further been pro-
posed in which the RCL is reversibly and partially
inserted, and the s1C is partially detached.1,20 Also,
a recent study using hydrogen–deuterium exchange
(HDX) detected transient unfolded states along the
reaction pathway to the latent state.21 However, the
timeframe for slower conformational steps during
the latency transition is currently not known.
To set the foundation for a temporal model of
latency transition under physiological conditions, we
directly targeted the RCL and covalently attached
the fluorescent NBD probe to single positions along
its length. We chose the RCL since it experiences
the greatest change in conformation during the tran-
sition and its orientation determines active versus
latent protein. We also chose the NBD probe due to
its potential to provide rich information, as exempli-
fied by its use to detect the biphasic binding of vitro-
nectin to PAI-1.22 We selected 13 residues spanning
P13–P50 of the RCL to monitor based on the contacts
formed in the latent conformation (Table I). [Resi-
dues of the RCL are assigned by their P designation
according to its distance from the P1–P10 scissile
bond, with C-terminal residues also indicated by a
prime (0).] We thereby measured the timescale for
conformational changes associated with the translo-
cation of the RCL to the shutter region and s1C
through the gate to the surface of PAI-1 via pin-
pointed changes in fluorescence during the latency
transition.
Results
Mutations and labeling modestly affect the
stability of PAI-1
We mutated single residues along the RCL to cyste-
ine and conjugated each with the NBD probe. To
determine if introduction of cysteine mutations or
labeling with NBD affects the function of PAI-1, sev-
eral assays with tPA were performed. Because suc-
cessful inhibition by PAI-1 depends heavily on its
correct folding, mutations that increase or decrease
Figure 1. The active and latent structures of PAI-1. The RCL (red) in the active structure of PAI-1 [PDB: 3Q02 (W175F)54] is
mostly unresolved (dotted line), while it is inserted as the fourth strand in the central b-sheet A (s4A) in the latent conformation
[PDB: 1C5G30]. Important functional regions in self-regulation by latency transition, including the gate (green), shutter (s5A/s3A,
cyan), helix F (and the loop connecting it to s3A) of the flexible joint regions (orange), and helix A (magenta) are also indicated.
Residues of the RCL are assigned by their P designation according to its distance from the P1–P10 scissile bond, with C-
terminal residues also indicated by a prime (0). The side chains of certain RCL residues are circled, and the molecular surface
of the latent structure included is colored according to the legend (bottom right).
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its inhibitory half-life as measured by this assay
effectively stabilize or destabilize the serpin, respec-
tively. As shown in Figure 2, most mutations to
cysteine confer similar stability or effect a slight sta-
bilization compared to native PAI-1 consistent with
previous data.23,24 Upon conjugation with NBD, the
half-life is increased for PAI-1 with probes at indi-
vidual positions closer toward the center of the RCL,
and peaks with NBD at the P8 position. With an
average half-life of 1.3 and 1.75 h for unlabeled
and labeled proteins, respectively, these changes in
the stability of PAI-1 are modest and indicate that
serpin folding and the overall mechanism of protease
inhibition are not perturbed by site-specific labeling.
Transition to the latent conformation is
accompanied by changes in NBD fluorescence
With our NBD-labeled PAI-1 proteins, we collected
fluorescence emission spectra after excitation at
480 nm and measured the rates of fluorescence
change over time. Representative plots showing dif-
ferences in fluorescence comparing active and latent
NBD-labeled PAI-1 variants are shown in the spec-
tra in Figure 3, corresponding to NBD probes at
select positions across the length of the RCL as
examples of the sensitivity of the measurements and
value of the point-specific probes as reporters. Fur-
thermore, the change in NBD fluorescence corre-
sponds with the loss of PAI-1 activity in inhibiting
tPA (Fig. 4).25 At 378C, NBD at proximal [Fig. 4(A)]
and distal [Fig. 4(B,C)] RCL positions exhibits an
exponential increase in fluorescence, indicating
movement of the probe into a more hydrophobic
environment, as expected from insertion of the RCL
into b-sheet A upon transition to the latent state
(Fig. 1).25 The half-lives determined from exponen-
tial fits to fluorescence measurements differed
slightly depending on the buffer that was used (Fig.
5). In light of these findings that demonstrate
buffer-specific effects on NBD-PAI-1 fluorescence
exhibited by probes along the RCL, we optimized the
buffer system and settled on the more physiologi-
cally relevant phosphate buffer for this study.8 This
change resulted in the modest stabilization of NBD-
PAI-1, with half-lives that are 1.3-fold longer in
the phosphate buffer at the same temperature and
Table I. Contact, Labeling, and Spectral Analysis of PAI-1 RCL Residues
Contact Emission Spectral Relative Relative Q
RCL
Analysisa
mol NBD/ Maximum Shift Q Yield:
Position Residue Activeb Latentc mol PAI-1d (nm)e (nm)e Yieldg Stoichiometry
P13 V334 1 0.63 531 6 3 0.8 6 0.6 0.47 0.74
P12 A335 0.63 530 6 3 6.7 6 1.2 0.45 0.72
P11 S336 1 0.96 533 6 4 3 6 1.4 n. d. n. d.
P9 S338 0.7 525 6 2 6 6 3.5 n. d. n. d.
P8 TSS9 2 0.98 525 6 2 5.8 6 0.3 n. d. n. d.
P6 V341 5 0.59 523 6 1 7.3 6 2.3 0.45 0.76
P5 I342 3 1.1 529 6 0 1.8 6 0.4 n. d. n. d.
P3 S344 1 0.98 529 6 2 0.7 6 0.3 0.43 0.44
P10 M347 1 1.16 532 6 2 1.5 6 1.4 0.42 0.36
P20 A348 0.71 531 6 2 1.3 6 1.8 0.41 0.58
P30 P349 0.91 528 6 5 4.5 6 1.8 0.41 0.46
P40 E350 1 4 1 526 6 2 4.5 6 3.1 n. d. n. d.
P50 E351 1 0.9 529 6 1 1.1 6 0.9f 0.41 0.46
a Based on total number of residue-to-residue hydrophobic, ionic, and hydrogen bonds.
b Based on 3Q02 structure of active PAI-1.52
c Based on 1C5G structure of latent PAI-1.30
d Corrected for NBD absorbance at 280 nm as indicated in Methods.
e Based on at least duplicate experiments.
f Bathochromic; all other shifts are hypsochromic.
g Based on single point determination; relative quantum yield of NBDfree was set to 0.5 assuming 50% efficiency.
Figure 2. Half-life of inactivation via protease inhibition.
Unlabeled (white bars) and NBD-labeled (black bars) PAI-1
proteins were incubated at 378C in MOPS buffer (0.05M,
0.1M ammonium sulfate, 1 mM EDTA, pH 7.4) and their activ-
ity assayed by the addition of tPA and excess Spectrozyme
tPA (a chromogenic substrate for tPA) at various time points.
Initial rates were plotted over time, and the inhibitory half-life
determined according to a one-phase decay model. Wild-
type (wt) and single-cysteine PAI-1 constructs according to
their P designation are indicated. Error bars are plotted as
standard deviations of triplicate experiments.
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pH (Fig. 5). We then measured the change in NBD
fluorescence along the RCL over time, which again
resulted in a single-exponential process correspond-
ing to the latency transition. From this exponential,
the half-lives of loop insertion were determined
[Fig. 6(A) and Table II]. In every case except for P50,
an increase in fluorescence over time is observed,
indicating burial of the NBD probe in or near the
hydrophobic core of the serpin. Also, with the excep-
tion of PAI-1 with NBD at the P12 position, the half-
life for PAI-1 is increased as probes are positioned
toward the middle of the RCL.
Due to some unusual and distinct fluorescence
properties, we were interested in analyzing the
kinetics for the transition with probes incorporated
at the P8 and P50 positions further (Fig. 7). First, in
contrast to all other positions, NBD at the P50 posi-
tion exhibits a consistent decrease in fluorescence
Figure 3. Active and latent fluorescence spectra for NBD along the RCL. NBD-PAI-1 (0.5 lM) was added to phosphate buffer
(0.05M NaH2PO4, 0.3M NaCl, 1 mM EDTA, 0.1% PEG8000, pH 7.4) at 378C, excited at 480 nm, and the emission spectra from
500 to 600 nm collected. The initial active (solid line) and final latent (dashed line) emission spectra are shown for several repre-
sentative variants of PAI-1 with NBD labels at different positions in the RCL.
Figure 4. Loss of PAI-1 activity and changes in NBD fluorescence. The residual activity of NBD-PAI-1 via tPA inhibition (left
axis), and the change in fluorescence emission at 530 nm over time after excitation at 480 nm (right axis) were measured at
378C in buffer with a pH of 7.4. The activity (solid circles) and fluorescence change (open squares) were measured in MOPS
buffer (0.05M, 0.1M ammonium sulfate, 1 mM EDTA) and phosphate buffer (0.05M NaH2PO4, 0.3M NaCl, 1 mM EDTA, 0.1%
PEG 8000), respectively, for PAI-1 labeled with NBD at the (A) P11, (B) P10, and (C) P40 positions. Data were normalized, aver-
aged, and then fit to a one-phase decay model. Error bars are plotted as standard deviations.
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over time, indicating an overall greater solvent expo-
sure at this position during latency [Fig. 7(A)]. Also,
based on the residuals and goodness of fit (R2), we
found that a single exponential fit for P8 and P50
was not adequate, and the data fits favored an alter-
native two-phase model [Fig. 7(A,B)]. The average
R2 significantly increased from 0.79 to 0.98 for P50
with this new analysis. For P50, the fast transition
has a half-life of 5 min, while the initial conforma-
tional change detected from the P8 position occurs
on an intermediate timeframe with a half-life of 25
min. The half-life for the slower transition at P8 and
P50 is 5.2 and 3.7 h, respectively (Table II). The
error calculated for the half-life of the slower transi-
tion at the P8 probe is the largest among all these
measurements, due to higher variability in the fluo-
rescence measurements at time points taken near
the end of the experiment. A global fit that included
all data from the three experiments using the P8
probe gave a half-life of 3.6 h for the slow phase
with an R2 of 0.94. Thus, the time frame calculated
for slow phase at P8 is on par with the times meas-
ured across the sequence of variants for the overall
latency conversion.
Although two-phase fits were clearly better for
the latency kinetics measured with probes at the P8
and P50 positions, this was not true for the kinetics
measured with probes at other positions in the RCL.
An example of the analyses with probes at other RCL
Figure 5. Stabilization of PAI-1. Buffer effects on NBD-PAI-1
activity were measured by incubation at 378C in either MOPS
(0.05M, 0.1M ammonium sulfate, 1 mM EDTA, pH 7.4) or
phosphate buffer (0.05M NaH2PO4, 0.3M NaCl, 1 mM EDTA,
0.1% PEG8000, pH 7.4). Samples were excited at 480 nm,
the fluorescence emission at 530 nm collected over time, and
fit to a one-phase decay model from which the half-life was
determined. Representative data are for NBD P9 (S339C)
PAI-1. Error bars are plotted as standard deviations of dupli-
cate experiments.
Figure 6. Half-life of RCL insertion via fluorescence. A. NBD-
labeled PAI-1 was added at 0.3–0.5 mM in phosphate buffer
(0.05M NaH2PO4, 0.3M NaCl, 1 mM EDTA, 0.1% PEG 8000,
pH 7.4) at 378C. Samples were excited at 480 nm and fluo-
rescence emission at 530 nm was plotted against time.
Except for P8 and P50, data were fit to a one-phase decay
model from which the half-life of the latency transition was
obtained. For P8 and P50, the half-life of the slow process
according to a two-phase decay model is plotted. B. The
overall change in fluorescence [(Ffinal 2 Finitial)/Finitial] upon
completion of the latency transition is plotted for NBD at all
RCL positions. Values are normalized to the initial fluores-
cence at 530 nm. Experiments were performed in at least
duplicate and plotted with standard deviation error bars.
Table II. Comparison of NBD-PAI-1 Half-Lives via
Protease Inhibition & Fluorescence Measurements
RCL
position Half-life (h)a Half-life (h)b Ratioc
P13 1.1 6 0.1 1.0 6 0.1 1
P12 1.2 6 0.03 7.2 6 1.2 6.1
P11 1.5 6 0.1 2.8 6 0.5 1.9
P9 1.7 6 0.1 3.2 6 0.7 1.9
P8 2.7 6 0.1 0.4 6 0.1 (fast) 1.9d
5.2 6 4.3 (slow)
P6 2.6 6 0.1 4.1 6 0.1 1.6
P5 2.3 6 0.1 5.5 6 0.5 2.4
P3 1.8 6 0.04 3.9 6 0.8 2.2
P10 1.8 6 0.1 4.1 6 0.8 2.3
P20 1.3 6 0.1 2.7 6 1.4 2.1
P30 1.6 6 0.03 2.3 6 0.1 1.4
P40 1.6 6 0.1 2.6 6 0.4 1.6
P50 1.7 6 0.1 0.1 6 0.03 (fast) 2.3d
3.7 6 0.8 (slow)
a Measured indirectly from assays of tPA activity over
time. Results are the average and standard deviation for
triplicate measurements.
b Based on fluorescence measurements over time. Results
are the mean and standard deviation for measurements
analyzed in triplicate for P13, P12, P11, P9, P8, P20, P40,
and P50 and duplicate for P6, P5, P3, P10, and P30.
c Between single exponential half-life measured by fluores-
cence to half-life measured indirectly via tPA activity.
d Between slow half-life from two-phase exponential fit of
data measured by fluorescence and half-life measured indi-
rectly via tPA activity.
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positions that gave little to no improvement with dou-
ble exponential fits is shown in Figure 7(C), with the
P13 variant. Similar to P13, analysis of all other
labeled PAI-1 variants besides P8 and P50 yielded
single-exponential fits that were sufficient and statis-
tically valid (Table II). Although some anomalies
were apparent at very early time points in some data
sets, these were not consistent and two-phase models
did not improve the overall fit. We compared differen-
ces in half-life measured by inhibition of tPA and flu-
orescence, and summarized these results in Table II.
In most cases, a 1–2.4-fold difference is observed.
For PAI-1 labeled with NBD at the P12 position, an
approximate sixfold difference is observed when half-
lives are derived from tPA inhibition versus fluores-
cence measurements. This difference indicates that
the probe at the P12 position interferes with RCL
insertion during the latency transition, but not its
insertion upon protease cleavage of the scissile bond
and suicide-complex formation.
The magnitude of the fluorescence change for
NBD at the RCL due to transition of PAI-1 to the
latent state is plotted in Figure 6(B) and spectral
analysis included in Table I. NBD at positions P9,
P6, and P40 exhibit the largest changes in fluores-
cence compared to the rest of the positions investi-
gated. For NBD-labeled PAI-1 proteins, the average
emission maximum is 530 nm, the spectral shift
upon completion of the latency transition is small
(<10 nm), and the relative quantum yield of NBD
along the RCL is similar. The overall fluorescence
change at the various positions is also independent
of the contacts formed in the latent state, labeling
stoichiometry, or relative quantum yield (Table I),
and is not due to polymerization of PAI-1 (data not
shown). For example, the P8 residue has a higher
labeling stoichiometry than the adjacent P9 residue,
but NBD at the P9 position exhibits a 5.43 more
intense fluorescence than it does at the P8 position.
Likewise, while the labeling stoichiometry and rela-
tive quantum yield of NBD at the P12 and P6 posi-
tions are very similar, the fluorescence change at
the P12 position is 4.33 less intense than at the
P6 position. Also, of the three positions that exhibit
Figure 7. Changes in NBD fluorescence at the P50, P8 and P13 RCL positions. PAI-1 (0.5 lM) with NBD conjugated to the (A)
P50, (B) P8, or (C) P13 residues was incubated in phosphate buffer (0.05M NaH2PO4, 0.3M NaCl, 1 mM EDTA, 0.1% PEG 8000,
pH 7.4) at 378C, excited at 480 nm, and emission at 530 nm plotted over time. Experiments were performed in at least tripli-
cate, but only a representative curve for each is shown. Data were fit to a one-phase (top) and two-phase (bottom) decay
model. Residual plots for each are included below their curves.
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the greatest fluorescence change during the transi-
tion, only the molecular surface surrounding posi-
tion P6 in the latent crystal structure is highly
lipophilic (Fig. 1). These results emphasize that the
unique microenvironment for individual residues
can be detected by the sensitive NBD probe, and
that changes in fluorescence at the RCL are site-
specific.
Discussion
Despite an array of studies that include extensive
mutagenesis, thermodynamic characterization, crys-
tallization, HDX-MS, and use of RCL-mimicking
peptides and monoclonal antibodies, the timescale
for events during the transition from active to
latent conformation of PAI-1 is still not well
defined.1,2,6,18,20,26–39 We thereby conjugated the flu-
orescent NBD reporter to single positions along the
RCL and observed the changes that occur during
this process. Significant effects on the stability or
fold were not observed nor expected for these
mutants (Fig. 2), as previous studies have shown
that the lability of PAI-1 is not in the sequence of
the RCL and its mutation is tolerated as long as the
P1 position is occupied by a basic residue, preferably
arginine, and not proline at the P10 position.40–42
Indeed, many studies have employed mutation and
labeling of the P9 position to elucidate events during
inhibition, interaction with target proteases, and
mechanism of inactivation by monoclonal antibod-
ies.1,13,15,22,23,25,43,44 Mutation and labeling of P14,
P13, P3, and P1013,24,44–47 have been used to a lesser
degree to provide information about RCL tethering
and nanosecond dynamics. Similar to these prior
studies, our results indicate that the PAI-1 RCL cys-
teine mutants are folded and function properly. Fur-
thermore, this study presents the most extensive
use of NBD to date for the comprehensive analysis
of the PAI-1 latency transition.
The use of site-specific probes reveals that the
residues along the length of the RCL reposition indi-
vidually, and somewhat different kinetics are associ-
ated with their final repositioning during the
latency transition. From measurements of tPA inhi-
bition and detection of fluorescence changes over
time, the half-life determined for PAI-1 is increased
as fluorescence labels conjugated at single positions
are placed closer to the P8 position [Figs. 2 and 6(A)
and Table II]. These results support a mousetrap-
like insertion mechanism, in which the proximal
and distal ends insert more rapidly than the apex of
the RCL, and were initially proposed from the study
in which “P-even” residues (that have side-chains
that point toward the hydrophobic core of PAI-1)
were mutated to glutamate to slow the latency
transition.30
The difference between half-lives measured by
tPA inhibition and fluorescence methods indicates
that the NBD probe provides a unique advantage in
reporting changes in the solvent environment during
the latency transition, while only modestly slowing
its rate (Table II). In fact, such perturbations—simi-
lar to those induced by mutations and/or changes in
temperature, pH, and solvent (e.g., D2O vs H2O)—
provide useful and invaluable information that
would have not otherwise been detected. Unsurpris-
ingly, 1–2.4-fold differences in half-life result from
perturbation of NBD upon RCL insertion, possibly
due to packing constraints, steric clashes, and/or
unfavorable interactions. The perturbation of NBD
at the P12 position is particularly significant, as evi-
dent by the 6.1-fold difference between half-life
measurements. Labeling PAI-1 at the P12 position
reverses the 1.4-fold stabilization due to mutation of
alanine to cysteine (Fig. 2). This reduced stability in
combination with the long half-life (7.2 h) meas-
ured by fluorescence indicates interference of NBD
at the P12 position with RCL insertion [Fig. 6(A)].
In addition, the significantly longer half-life for PAI-
1 with NBD at the P12 position compared to PAI-1
with probes at adjacent positions indicates that the
hinge where the RCL begins to insert as the fourth
strand of b-sheet A (s4A) is tightly packed, and that
preinsertion here must occur for latency to com-
mence. Moreover, preventing this preinsertion of the
P12 residue to delay the latency transition is a
potential strategy to inhibit PAI-1.
In addition to demonstrating that there are some
interesting site-specific features of the latency transi-
tion, investigation of particular residues with more
complicated kinetic behavior offered other insights.
In most cases, the changes in NBD fluorescence along
the RCL are adequately described by a single expo-
nential process, but the kinetics of fluorescence
change for labels at the P8 and P50 positions are bet-
ter explained by a two-step process (Fig. 7). For
probes at these two positions, the slower phase has a
half-life of several hours, consistent with the rates for
loop rearrangement in the latency conversion that
are observed throughout the RCL. However, the early
phases exhibited by probes at the P8 and P50 posi-
tions have different half-lives and report changes
that are site-specific due to their unique locations.
For the P50 residue, which is located at s1C in the
active conformation, the early transition is a decrease
in fluorescence that occurs with a half-life of 5 min.
This increase in solvent exposure is consistent with
s1C detachment at the P50 position. Upon strand
detachment, the probe at the P50 position continues
to exhibit a decrease in fluorescence during the slow
phase. This indicates that the environment for the
P50 residue after passing through the gate and adopt-
ing a flexible loop conformation in the latent state of
PAI-1 is also hydrophilic, which is expected for its
location at the surface of the serpin. Also, since a
detached s1C is characteristic of the prelatent
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conformation, our results indicate that the changes to
adopt this conformation begin early during the
latency transition.20
In crystal structures, the P8 residue is located
within the mobile portion of the RCL in the active
state of PAI-1; following the latency transition, it
occupies a position under the apex of hF (Fig. 1).
Analysis with the two-phase kinetic model yields a
fast half-life of 25 min, representing a step inter-
mediate between the rapid detachment of s1C (5
min as reported from P50) and the slow repositioning
of the RCL as s4A (hours). We hypothesize that this
intermediate event represents displacement of hF
and the loop connecting it to s3A to facilitate inser-
tion of the RCL in the latent conformation. The
steric barrier presented by hF/s3A loop displacement
is also consistent with the observation of a peak
half-life for PAI-1 labeled at P8 position (Figs. 2 and
6). Once hF is displaced, consecutive residues can
insert with ease. Whether hF/s3A loop displacement/
repositioning or passage of the RCL through the
gate region is the rate-limiting step of the latency
process is not apparent from this study and will
require further investigation. The results, which
leverage site-specific probes at P50 and P8, reveal
intermediate events in the latency transition that
provide important details relevant to our previous
approach-to-equilibrium kinetic study on metal bind-
ing to PAI-1 that demonstrate one or more conforma-
tional intermediates that occur after metals bind
and induce the latency transition.8,48 Furthermore,
they expand on data from recent molecular modeling
using variable path sampling that support a long-
lived prelatent intermediate in the active-to-latent
transition from molecular modeling using variable
path sampling.49 Consistent with our findings, the
molecular modeling study documents detachment of
s1C as a requisite for the prelatent intermediate
and a high-energy barrier involving displacement of
hF that must be overcome to reach the final latent
state.
For the first time, our experimental approach
defines the relative timeframe for these discrete
steps in the sequence of the events in the latency
process, outlined in the model shown in Figure 8.
Starting from the native, metastable state (struc-
ture A), the RCL is extended, but close to the pro-
tein core.24 Within the first 5 min of the latency
process, s1C becomes partially detached (structure
B).20 The changes that occur from structure A to B
may or may not be coincident with the transient
unfolding of helix A and strand 5 of b-sheet A (s5A)
in the shutter (c.f. Fig. 1).21 As PAI-1 becomes
latent, the central b-sheet partially opens.50 This
opening allows the reversible and partial insertion
of the N-terminal portion of the RCL (structure C).
The latter conformation is representative of the
hypothetical prelatent conformation of PAI-1.1,20,24,49
For further RCL insertion, the gate must widen
(structure D) and hF/s3A loop must be displaced
(structure E), which may occur in concert within
the next 30 min of the latency process.51 Also, the
C-terminal RCL (i.e., detached s1C) must pass
through the gate region (structure F). This period
involving the conformation changes represented in
structures E and F may represent the rate-limited
step of the latency process. With hF/s3A loop dis-
placed, consecutive N-terminal RCL residues can
insert. Once the latter are fully inserted as s4A, and
C-terminal RCL extended along the surface of the
serpin (structure G), hF can return to its position
over the shutter (structure H). Thus, the latency
transition is completed within the half-life of 1–
2 h. Many of these conformational changes during
Figure 8. Temporal model of PAI-1 latency transition. The RCL is shown in red, with s1C depicted as a red arrow, the gate
loops in green, the shutter b-strands as blue arrows, and hF as an orange cylinder. Additional strands of the central b-sheet A
are shown as grey arrows. Starting from the native, metastable state (A), the RCL is extended, but close to the protein core. In
the steps toward the latent conformation, the shutter partially opens (B). This allows the RCL to partially insert and s1C to par-
tially detach, reversibly, in the prelatent conformation (C). For further RCL insertion, the gate must widen (D) and hF must be
displaced (E). The C-terminal RCL may then pass through the gate and consecutive N-terminal RCL residues insert as s4A (F).
When the N-terminal RCL is fully inserted as s4A and C-terminal RCL extended along the surface of the serpin (G), hF returns
to its position over the shutter and the latency process is completed (H).
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latency, including opening of the shutter, RCL inser-
tion, and hypothesized movements of hF, parallel
those that occur during inhibition by PAI-1.15,30,51,52
Using site-specific fluorescence to explore
changes in RCL conformation over time and space,
we conclude that s1C detachment occurs early in the
transition from active to latent PAI-1, corresponding
to a transition that occurs in the initial 5 min of
the latency process that has a half-life on the order
of 1 h. The detachment of s1C is followed by a
slower step that is sensed at position P8 in the RCL,
a region that is particular sensitive to changes in
hF, which must be displaced to allow the RCL to be
inserted into the central b-sheet A of PAI-1. On the
long time-scale that represents an en bloc reposition-
ing of the loop, RCL insertion is slow. The process of
RCL insertion may be limited by passage of C-
terminal residues through the gate or by hF dis-
placement (and finally repositioning) that allows the
threading of the N-terminal sequence into sheet A
and assumption of the final latent conformation. In
future studies, this strategy will be a useful method
to define timescales and structural restrictions to
hone in on individual events during the latency
transition. Such studies have the potential to eluci-
date the rate-limiting step for the latency transition
(e.g., by NBD probes strategically positioned in the
gate region and hF/s3A loop), and uncover new tar-
gets to inhibit pathophysiological PAI-1.
Methods
Analysis of protein contacts and molecular
surface rendering
Contact analysis in active (3Q02) and latent (1C5G)
PAI-1 was reported using MOE 2012.10 to list atoms
between two residues in the same chain, but not
restricted to residue or chain selection, that partici-
pate in a hydrophobic, ionic, and/or hydrogen bond.
Side-chain and main-chain hydrogen bonds, but not
inferred bonds, are included. Hydrophobic and ionic
bonds are defined by proximity with a distance cut-
off of 4.5 Å. Met and His were treated as hydropho-
bic and basic, respectively. The molecular surface
according to lipophilicity under default parameters
was also computed in MOE.
PAI-1 RCL mutagenesis and purification
Oligonucleotide primers were designed to contain a
cysteine mutation at the desired RCL position (wild-
type PAI-1 does not contain any intrinsic cysteine
residues). Mutations were introduced to the human
PAI-1 cDNA (previously cloned into the pET24d(1)
vector, a gift from Grant Blouse, Henry Ford Health
Sciences Center Detroit, MI) via PCR using the
Quik Change II XL Site-directed Mutagenesis kit
(Stratagene Inc., Cedar Creek, TX). Correct mutants
were transformed into Escherichia coli Rosetta 2
DE3 pLysS cells (Invitrogen) for growth, expression,
and large-scale cell harvest. Typical conditions for
growth were 30–378C with shaking at 250–300 rpm
in Terrific Broth (RPI Corp, Mount Prospect, IL)
supplemented with 50 lg/mL kanamycin and 34 lg/
mL chloramphenicol (RPI Corp). At mid- to late-log
phase, cells were cooled to 158C, induced with 1 mM
IPTG, and grown overnight. Cells were harvested by
centrifugation, treated with protease inhibitor cock-
tail (#P8465, Sigma Alderich Corp., St. Louis, MO),
and lysed by sonication. PAI-1 proteins were purified
at 48C in the presence of 1 mM dithiothreitol (DTT)
in three consecutive steps involving cation exchange
on SP-Sepharose FF, IMAC on chelating-Sepharose
FF charged with nickel, and size-exclusion on
Sephacryl S-100 HR resin (GE Healthcare, Piscat-
away, NJ), and stored at 2808C in phosphate buffer
(0.05 M NaH2PO4, 0.3 M NaCl, 1 mM EDTA, 1 mM
DTT, pH 6.25). The purified proteins were subjected
to SDS-PAGE followed by Western blotting (rabbit
anti-human PAI-1, Molecular Innovations Inc., Novi,
MI) and MALDI-TOF-MS (Bruker Daltonics Micro-
Flex) to confirm the identity and purity for each con-
struct. All protein samples were HPLC-purified
(Agilent Technologies 1200 Series) from a C18 col-
umn (Phenomenex Jupiter4u Proteo 90 Å) using a
linear 5–95% acetonitrile gradient and mixed with
sinapic acid (2.5 mg/mL, Fluka) prior to analysis by
mass spectrometry.
Functional distribution of PAI-1 proteins
tPA was titrated with varying amounts of PAI-1,
ranging from sub-stoichiometric to excess concentra-
tions, and incubated for 30 min at ambient tempera-
ture in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
NaH2PO4, 1.8 mM KH2PO4, pH 7.4). Reactions were
analyzed by SDS-PAGE under nonreducing condi-
tions and a digital image of the gel created using
the Bio-Rad Photo Documentation System (ChemDoc
XRS Software). To quantify the amount of active,
dimeric, latent, and cleaved PAI-1 that is observed
for these preparations, densitometry of each band in
the lane corresponding to 1:1 PAI-1:tPA was per-
formed using Bio-Rad Quantity OneTM software.
The results were normalized to percent of total
intensity after background subtraction. The mean
distribution for the preparations was 75% active,
13% cleaved substrate, 12% latent, and 1% dimeric
PAI-1.
Labeling of PAI-1 RCL
DTT was removed from the purified proteins via a
PD-10 column (GE Healthcare Life Sciences) and
eluted in phosphate buffer (0.05 M NaH2PO4, 0.3 M
NaCl, 1 mM EDTA, pH 6.6) at 48C. The fluorescent
NBD probe (IANBD, #D-2004, Invitrogen Molecular
Probes) was dissolved in DMSO, added at 203 molar
excess in 10% of the total reaction volume, and
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incubated (covered) on ice at 48C overnight to label.
After incubation, free probe was removed by an
additional PD-10 step. NBD-labeling was confirmed
by MALDI-MS as described above, and labeled pro-
teins stored at 2808C in phosphate buffer (0.05 M
NaH2PO4, 0.3 M NaCl, 1 mM EDTA, pH 6.6). The









where ANBD is taken at 492 nm, the extinction coef-
ficient for NBD, eNBD, is 25,000 M
21 cm21, and the
MW of recombinant unglycosylated human PAI-1
used for the calculation is 43,000 mg/mmol. The
absorbance of NBD at 280 nm was corrected as pre-
viously described.25,44
Single-point relative quantum yield
determination
To determine the relative contribution of the effi-
ciency of NBD fluorescence to the magnitude of
fluorescence changes observed, single-point meas-
urements were taken to estimate the relative quan-
tum yield for NBD-PAI-1. Based on labeling
stoichiometry, NBD-PAI-1 concentration was
adjusted to 0.25 lM NBD in 2 mL buffer containing
50 mM NaH2PO4, 300 mM NaCl, 1 mM EDTA, 0.1%
PEG 8000 (w/v), pH 7.4. Samples were added to a
PEG-coated cuvette and placed in a Perkin Elmer
LS 50B Luminescence spectrometer connected to cir-
culating water bath (Lauda-Brinkmann RM6) set
such that the temperature in the chamber was 378C.
Absorbance scans from 400 to 520 nm and emission
scans from 500 to 600 nm were collected. Emission
scans were collected after excitation at 480 nm. The
absorbance at the theoretical wavelength maximum
of 480 nm for NBD and the area of fluorescence of
the emission were used to calculate the relative
quantum yield using the following equation:







where Qprot and Qref are the relative quantum yield
of NBD-PAI-1 and NBDfree, respectively, A is the
absorbance at 480 nm, and
Ð
I is the integral of the
intensity of the fluorescence emission (i.e., area of
fluorescence).
Ð
I was calculated using GraphPad
Prism software. Qref was arbitrarily set to 0.5,
assuming 50% efficiency for NBDfree.
Inhibitory activity of PAI-1 RCL constructs
Unlabeled and NBD-labeled PAI-1 proteins were
added at a concentration in which the quantity of
active protein was 1:1 with 0.1 lM tPA (#HTPA-TC,
Molecular Innovations, Novi, MI). PAI-1 was incu-
bated at 378C in MOPS buffer (0.5 mM, 0.1 M
ammonium sulfate, 0.1 mM EDTA, pH7.4) and
reacted with 0.1 lM tPA at various time points. Ini-
tial rates were measured by adding excess Spectro-
zyme tPA (American Diagnostics Inc., Stamford, CT)
to the reactions and recording the absorbance of p-
nitroaniline at 405 nm for 5 min. The slope obtained
from the latter was plotted against each time point
as tPA activity. The residual PAI-1 activity was cal-
culated as the negative of tPA activity, normalized,
and fit to a one-phase exponential decay model using
GraphPad Prism Version 5.0b. The corresponding
active half-lives for PAI-1 proteins were determined.
All experiments were performed in triplicate and
data were collected for 10 half-lives.
PAI-1 RCL fluorescence measurements and
half-life determination
NBD-labeled PAI-1 proteins (0.3–0.5 lM) were added
in 2 mL phosphate buffer (0.05 M NaH2PO4, 0.3 M
NaCl, 1 mM EDTA, 0.1% PEG 8000, pH 7.4) or
MOPS buffer (0.05 M, 0.1 M ammonium sulfate,
1 mM EDTA, pH 7.4) to an acrylic cuvette, PEG-
coated as previously described.53 Cuvettes were
sealed (Mylar plate sealer, Thermo Scientific) and
placed in a luminescence spectrometer (Perkin
Elmer LS 50B) connected to circulating water bath
(Lauda-Brinkmann RM6) set such that the tempera-
ture in the chamber was 378C. Samples were excited
at 480 nm and fluorescence emission spectra from
500 to 600 nm were collected every 5 min (for 5–7 h)
followed by at least 3 time points at long intervals to
determine the final fluorescence value after the
latency transition. Results are plotted as the nor-
malized intensity at the average wavelength maxi-





where F is the fluorescence intensity at 530 nm at a
given time point, and F0 5 Fmin, which is the lowest
fluorescence intensity at 530 nm measured over
time. The plots of the normalized fluorescence over
time were analyzed using GraphPad Prism Version
5.0b and fit to a one-phase or two-phase exponential
model from which the half-life of loop insertion was
determined. All experiments were performed in trip-
licate, except for the variants labeled at P6, P5, P3,
P10, and P30, which were only performed in
duplicate.
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